MedDRA preferred term

Pulmonary alveolar haemorrhage: adverse event reports recording this term

5,521 reports to FDA record it, 2004–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

5,521
reports recording the term: 0% of all reports; 432
reports, 12 months to June 2026: 481 in the 12 months before; 99.7%
marked serious by the reporter: 57.4% across all reports; 36.1%
record death among outcomes, as reported: 9.1% across all reports

5,521 reports in FDA's adverse event database record the MedDRA term "Pulmonary alveolar haemorrhage": 0% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

432 reports recorded it in the 12 months to June 2026, down 10% from 481 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 99.7% are marked serious, 36.1% include death among the outcomes and 63% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Prednisone, Levofloxacin and Cyclophosphamide. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Prednisone	Corticosteroid	415	0.2%
Levofloxacin	Fluoroquinolone antibacterial	242	0.8%
Cyclophosphamide	Alkylating drug	240	0.2%
Eliquis	Factor Xa inhibitor	223	0.2%
Azathioprine	Purine antimetabolite	202	0.6%
Albuterol	beta2-Adrenergic agonist	201	1.1%
Magnesium oxide	Calculi dissolution agent	201	10.4%
Calcium carbonate	Blood coagulation factor	195	2.2%
Hydralazine	—	194	4.5%
Ergocalciferol	Provitamin D2 compound	193	1.9%
Budesonide	Corticosteroid	190	1.3%
Furosemide	Loop diuretic	187	0.4%
Xarelto	Factor Xa inhibitor	187	0.1%
Insulin glargine	Insulin analog	182	0.7%
Aspirin	Nonsteroidal anti-inflammatory drug	181	0.3%
Apixaban	Factor Xa inhibitor	174	0.4%
Azithromycin	Macrolide antimicrobial	171	1%
Tacrolimus	Calcineurin inhibitor immunosuppressant	168	0.2%
Clotrimazole	Azole antifungal	165	6%
Pantoprazole magnesium	—	163	8.3%
Candesartan	Angiotensin 2 receptor blocker	162	1.6%
Mycophenolate mofetil	Antimetabolite immunosuppressant	161	0.2%
Cephalexin	Cephalosporin antibacterial	160	2.8%
Clopidogrel	P2Y12 platelet inhibitor	160	0.5%
Nucala	Interleukin-5 antagonist	159	0.5%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Corticosteroid	1,348	0.2%	0%
Factor Xa inhibitor	643	0.2%	0.2%
Cephalosporin antibacterial	524	0.9%	0%
Fluoroquinolone antibacterial	406	0.5%	0%
Purine antimetabolite	384	0.8%	0.6%
Alkylating drug	377	0.1%	0%
beta2-Adrenergic agonist	354	0.4%	0.1%
Anticholinergic	333	0.2%	0%
Insulin analog	321	0.1%	0%
Loop diuretic	319	0.5%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.9%49

2 to 111.2%67

12 to 171.9%105

18 to 4416.6%918

45 to 6420%1,103

65 to 7423.3%1,287

75 and over17.6%974

Age not given18.4%1,018

Patient sex

Female35.3%1,949

Male52.3%2,885

Not given12.4%687

Grey bar: all 20,646,523 reports in the database. 40.8% of these reports give the United States as the country.

Questions about "Pulmonary alveolar haemorrhage"

What does "Pulmonary alveolar haemorrhage" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record pulmonary alveolar haemorrhage?

5,521 reports through June 2026 (0% of all reports), 432 of them in the latest 12 months.

Which drugs appear most often in these reports?

Prednisone (415), Levofloxacin (242), Cyclophosphamide (240), Eliquis (223) and Azathioprine (202). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.